Autopsy report · NCT03866798

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

Cause of deathRegulatory or ethics Automatic label, confidence 0.9, unverified. How labels are made.

“FDA released Octapharma from the pediatric post marketing requirement.”

The sponsor’s own words in the registry.

Life of this trial

Registered 10 months before it started.
Ran for about 4 years 4 months before it stopped.
6 participants enrolled.
Results were posted on the registry 3 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 4
Sponsor: Octapharma
Sponsor type: Industry
Conditions: Chronic Immune Thrombocytopenia
Interventions: Panzyga
Participants: 6
Sites: 8
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.